BR112023002139A2 - Compostos de heterobiarila e agentes de imageamento para proteína huntingtina - Google Patents

Compostos de heterobiarila e agentes de imageamento para proteína huntingtina

Info

Publication number
BR112023002139A2
BR112023002139A2 BR112023002139A BR112023002139A BR112023002139A2 BR 112023002139 A2 BR112023002139 A2 BR 112023002139A2 BR 112023002139 A BR112023002139 A BR 112023002139A BR 112023002139 A BR112023002139 A BR 112023002139A BR 112023002139 A2 BR112023002139 A2 BR 112023002139A2
Authority
BR
Brazil
Prior art keywords
imaging agents
huntingtin protein
compounds
heterobiaryl
heterobiaryl compounds
Prior art date
Application number
BR112023002139A
Other languages
English (en)
Inventor
Liu Longbin
Dominguez Celia
Chen Xuemei
E Mangette John
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of BR112023002139A2 publication Critical patent/BR112023002139A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTOS DE HETEROBIARILA E AGENTES DE IMAGEAMENTO PARA PROTEÍNA HUNTINGTINA. São fornecidos no presente documento determinados compostos e agentes de imageamento úteis para detectar uma doença ou afecção associada à agregação de proteína, composições dos mesmos e métodos de seus usos.
BR112023002139A 2020-08-06 2021-08-05 Compostos de heterobiarila e agentes de imageamento para proteína huntingtina BR112023002139A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062310P 2020-08-06 2020-08-06
PCT/US2021/044702 WO2022031946A1 (en) 2020-08-06 2021-08-05 Heterobiaryl compounds and imaging agents for imaging huntingtin protein

Publications (1)

Publication Number Publication Date
BR112023002139A2 true BR112023002139A2 (pt) 2023-04-18

Family

ID=77739125

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002139A BR112023002139A2 (pt) 2020-08-06 2021-08-05 Compostos de heterobiarila e agentes de imageamento para proteína huntingtina

Country Status (10)

Country Link
EP (1) EP4192819A1 (pt)
JP (1) JP2023536886A (pt)
KR (1) KR20230054685A (pt)
CN (1) CN116323583A (pt)
AU (1) AU2021322253A1 (pt)
BR (1) BR112023002139A2 (pt)
CA (1) CA3190418A1 (pt)
IL (1) IL300394A (pt)
MX (1) MX2023001384A (pt)
WO (1) WO2022031946A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632899A1 (en) * 2009-05-29 2020-04-08 RaQualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
AU2012300246A1 (en) * 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP6254169B2 (ja) * 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
SG11201701600QA (en) * 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein

Also Published As

Publication number Publication date
IL300394A (en) 2023-04-01
AU2021322253A1 (en) 2023-02-23
US20220040336A1 (en) 2022-02-10
KR20230054685A (ko) 2023-04-25
JP2023536886A (ja) 2023-08-30
MX2023001384A (es) 2023-04-26
EP4192819A1 (en) 2023-06-14
WO2022031946A1 (en) 2022-02-10
CN116323583A (zh) 2023-06-23
CA3190418A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
Lieberman et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
Hu et al. p53 signalling controls cell cycle arrest and caspase‐independent apoptosis in macrophages infected with pathogenic L eptospira species
Planer et al. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi
CO2018009434A2 (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue
BR112023015045A2 (pt) Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
US20180360819A1 (en) Anti-influenza virus agent and screening method for anti-influenza virus agent
BR112017004141A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112017004899A2 (pt) detecção de proteínas mal dobradas
BR112022007612A2 (pt) Inibidores de raf quinases
BR112015020235A2 (pt) fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit
BR112017004056A2 (pt) composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
BR112023022836A2 (pt) Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
BR112018015155A2 (pt) métodos para determinação da presença ou ausência de um micro-organismo em uma amostra, para testar rapidamente uma matriz alimentar e um micro-organismo alvo, e, composição.
Guo et al. Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers
BR112019005995A2 (pt) cristal não solvatado, método de preparação e aplicação do mesmo
BR112018013327A2 (pt) aplicações de calimicina na resistência à infecção por mycobacterium tuberculosis
Hos et al. TRIM21 is targeted for chaperone-mediated autophagy during Salmonella typhimurium infection
CL2022001970A1 (es) Conjugados de proteínas-compuestos antivirales
BR112023002139A2 (pt) Compostos de heterobiarila e agentes de imageamento para proteína huntingtina
BR112018068414A2 (pt) derivados de ácido a-truxílico e composições farmacêuticas dos mesmos
BR112023020857A2 (pt) Compostos de isoindolinona e agentes de imaginologia para imaginologia da proteína huntingtina
BR112023022442A2 (pt) Compostos deuterados e agentes de imaginologia para imaginologia de proteína huntingtina